David S. Kabakoff
Independent Chairman of the BoardMr. David S. Kabakoff, Ph.D., is Chairman of the Board of Universal Preservation Technologies, Inc. He is Executive Advisor of Private Equity of Sofinnova Investments, Inc. from 2026. He joined the Sofinnova Investments, Inc. in 2007. He was Executive Partner of Private Equity of Sofinnova Investments, Inc. from 2007 to 2026. He is Director of BioTheranostics, Inc. from January 29, 2016. He joined the BioTheranostics, Inc. on January 29, 2016. He is Director of Lineagen, Inc. He joined the Lineagen, Inc. on February 18, 2015. He is Chairman of Trius Therapeutics LLC. He joined the Trius Therapeutics LLC in March 2006. He is Director of RareCyte, Inc. from 2020. He is Director of Rainier Therapeutics, Inc. He is Director of Dauntless Pharmaceuticals, Inc. He is Independent Chairman of the Board of NextCure, Inc. from December 2015. He joined the NextCure, Inc. in December 2015. He is Founding Senior Partner of HealthQuest Capital. He joined the HealthQuest Capital in 2012. He was Senior Partner of HealthQuest Capital from 2012. He is Director of Dauntless 2, Inc. He is Board of Manager of NYBC Ventures from October 2024. He was Director of Avalon Pharmaceuticals, Inc. He joined the Avalon Pharmaceuticals, Inc. on October 11, 2006. He was Director of InterMune, Inc. He was employed at InterMune, Inc. from November 01, 2005 to September 29, 2014. He was Director of Principia Biopharma Inc. He was Chairman of the Board, Chief Executive Officer and President of Spiros Development Corp. He joined the Spiros Development Corp. in 1997. He was President of Dura Technologies of Dura Pharmaceuticals, Inc. He joined the Dura Pharmaceuticals, Inc. in 1998. He was Chairman, Chief Executive Officer and President of Salmedix Inc. He joined the Salmedix Inc. in February 2001. He was Chairman of Amplimmune, Inc. He was Board Observer of Intellikine LLC. He was Chairman of The Board of CEBIX Inc. He joined the CEBIX Inc. in 2012. He was Director of Castle Biosciences, Inc. from May 2021 to August 05, 2021. He was Independent Director of Castle Biosciences, Inc. from September 2017 to 2021. He was employed at Castle Biosciences, Inc. from September 2017 to August 05, 2021. He was Director of Antiva Biosciences, Inc. from August 2015 to 2023. He was employed at Antiva Biosciences, Inc. from August 06, 2015 to 2023. He was Director of Neurana Pharmaceuticals, Inc. He was Director of Allylix, Inc. He has Ph.D. in Chemistry from Yale University, B.A. in Chemistry from Case Western Reserve University.
Positions
- Company NameNextCure, Inc.Stock CodeNXTCPositionIndependent Chairman of the BoardColleagues
- MSMichael S. RichmanCo-Founder, CEO, President & Director
- TMTimothy MayerChief Operating Officer
- LCLieping ChenCo-Founder & Chairman of Scientific Advisory Board
- SPSteven P. CobournChief Financial Officer
- KGKevin G. ShawSenior VP & General Counsel
- EVElaine V. JonesIndependent Director
- SWStephen W. WebsterIndependent Director
